retatrutide greece triples weight loss in obesity trial | Amr El-Refaey CMI Level 7 Strategic Management Certificate posted on the topic Lilly's Retatrutide: Toward the End

Only one study (Martin et al., 2025) tested a newer-generation agent, tirzepatide, a dual GIP/GLP-1 receptor agonist

The weight loss was gradual, with results beginning at around week four and continuing to increase until the end of the trial at week 24

Insulin moves sugar that comes from the breakdown of food out of the blood and into cells that need it

It is an investigational triple hormone receptor agonist

Nicotinic Acid, Nicotinamide, and Nicotinamide Riboside: A Molecular Evaluation of NAD Precursor Vitamins in Human Nutrition. Annual Review of Nutrition , vol

The MOTS-c peptide research is particularly relevant here, as MOTS-c affects mitochondrial function and exercise capacity in ways that could complement the metabolic effects of retatrutide